The prevalence of inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn’s disease (CD), increases gradually worldwide in the past decades. IBD is generally associated with the change of the immune system and gut microbiota, and the conventional treatments usually result in some side effects. Bifidobacterium longum, as colonizing bacteria in the intestine, has been demonstrated to be capable of relieving colitis in mice and can be employed as an alternative or auxiliary way for treating IBD. Here, the mechanisms of the Bifidobacterium longum in the treatment of IBD were summarized based on previous cell and animal studies and clinical trials testing bacterial therapies. This review will be served as a basis for future research on IBD treatment.

中文翻译：

---

长双歧杆菌：预防炎症性肠病

在过去的几十年里，炎症性肠病 (IBD) 的患病率，包括溃疡性结肠炎 (UC) 和克罗恩病 (CD)，在全球范围内逐渐增加。IBD通常与免疫系统和肠道微生物群的变化有关，常规治疗通常会产生一些副作用。长双歧杆菌作为肠道中的定植细菌已被证明能够缓解小鼠的结肠炎，并可用作治疗 IBD 的替代或辅助方法。在此，基于先前的细胞和动物研究以及测试细菌疗法的临床试验，总结了长双歧杆菌治疗 IBD 的机制。该综述将作为未来 IBD 治疗研究的基础。